How to buy Eli Lilly (LLY) stock from India

Yes, an Indian resident can buy Eli Lilly — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). The buying is the easy 10%. The 90% that decides your outcome is tax, estate-tax exposure, and position sizing. LLY pays a small but rising dividend, so 25% US withholding and Form 67 come into play every year. This is the short version.

The 30-second version

• Legal and simple. Buy LLY via any India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). Fractional matters here because LLY trades at a high absolute price.
• The GLP-1 story. Mounjaro (tirzepatide) and Zepbound are blockbuster dual GLP-1/GIP agonists that have reshaped obesity treatment. Pipeline: retatrutide (triple agonist) and oral orforglipron — potentially the mass-market unlock.
• India tax: hold more than 24 months and pay 12.5% LTCG (no indexation); sell sooner and pay your slab rate. Section 112, not the friendlier 112A that Indian shares get.
• Dividend admin is real. LLY yields roughly 0.6 to 0.8%. The US withholds 25% at source (reduced from 30% only because you filed W-8BEN under the India-US DTAA), and you reclaim it in India via Form 67 (Form 44 from TY 2026-27).
• The trap most miss: directly-held LLY is a US-situs asset — above $60,000, your estate faces up to 40% US estate tax, with no India-US treaty relief.
• If your thesis is "US pharma" or "GLP-1," XLV and IHE hold LLY at a meaningful weight; HRTS and SLIM are the most concentrated single-theme play.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	LLY / NYSE
How	India-facing platform (Vested, INDmoney) or global broker (IBKR, Rovia)
Minimum	A fraction of one share (fractional matters — LLY is a high absolute price)
Dividend	Yes — roughly 0.6 to 0.8% yield; quarterly
US dividend withholding	25% via India-US DTAA (W-8BEN required)
India tax on gains	12.5% LTCG after 24 months; else your slab (Section 112)
Estate-tax risk	US-situs above $60k means up to 40%, no treaty relief
Annual compliance	Schedule FA + Form 67 for the dividend FTC

How to buy it — 3 steps

1. Open an account and finish KYC. Pick an India-facing platform (Vested, INDmoney) for a simple India-funded experience, or a global broker (Interactive Brokers, Rovia) for wider access. File your W-8BEN during onboarding — this drops US dividend withholding from 30% to 25% under the India-US treaty and must be on file before the first dividend pays out. New to this? Start with how to invest in US stocks from India.
2. Fund it via the LRS. Remit from your Indian bank under the LRS (cap: $250,000 per financial year). 20% TCS applies above ten lakh rupees in a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator.
3. Place the order. LLY trades in the high hundreds of dollars per share — use fractional buying to size the position exactly rather than rounding to whole shares.

The tax that actually matters

Two things tax you here: dividends, every quarter; and capital gains, when you sell.

• US withholds 25% at source on each LLY dividend — the treaty rate under the India-US DTAA, available only if your W-8BEN is on file with your broker (else default 30%).
• In India, the gross dividend is added to total income and taxed at slab. You claim the 25% already withheld as a Foreign Tax Credit (FTC) by filing Form 67 before your ITR. From TY 2026-27, Form 67 becomes Form 44 — same purpose, renumbered under the revamped framework.

LLY's yield is low, so absolute rupee impact is small — but the paperwork is the same as for a 4% yielder. Treat it as a fixed annual cost.

Capital gains run under Section 112 (foreign shares don't get the Section 112A treatment Indian-listed equity enjoys):

Holding period	Treatment	Rate
24 months or less	Short-term	Your slab rate (up to roughly 30% plus surcharge)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 2 shares at $800 when USD/INR is 86 → cost 1,37,600 rupees. Sell 28 months later at $900 when USD/INR is 88 → proceeds 1,58,400 rupees. Taxable gain 20,800 rupees; LTCG at 12.5% = 2,600 rupees. The gain is computed in rupees, so a weaker rupee at sale amplifies your reported gain. Model your own with the US capital-gains calculator; full rules in how US stocks are taxed in India. For the dividend side, see dividend withholding and Form 67.

The $60,000 estate-tax trap

Directly-held LLY is a US-situs asset. If the holder dies with more than $60,000 of US-situs assets, the estate faces US estate tax up to 40% — and the India-US treaty does not cover estate tax, so there's no credit or relief. At LLY's price level, $60k is roughly seventy shares — not a hard ceiling for a high-conviction position. The fix (holding through pooled or fund structures rather than direct shares) has to be a deliberate choice made before the position gets large. Full detail: the $60,000 estate-tax trap.

Buy the stock, or get Eli Lilly through an ETF?

If you want…	Best route
A concentrated bet on the GLP-1 / obesity franchise	LLY directly
"US large-cap" with LLY as a top-weight constituent	VOO, VTI, or QQQ
Healthcare-sector exposure with LLY as a major weight	XLV (broad healthcare) or IHE (US pharma)
The most concentrated obesity / GLP-1 theme	HRTS or SLIM — LLY and NVO dominate the basket

LLY is a top constituent in VOO, VTI, and QQQ, and a heavy weight inside XLV (healthcare) and IHE (US pharma). The purest single-theme route is an obesity-focused ETF like HRTS or SLIM, where LLY and Novo Nordisk dominate the basket. Compare the routes in direct stocks vs US ETFs and best US ETFs for Indian investors; the broader case is in US ETFs for Indians.

The business in one screen

What it is: Eli Lilly is the Indianapolis-based pharma giant that has, in the last three years, become the defining obesity-and-diabetes franchise of the decade. Mounjaro (tirzepatide) treats type-2 diabetes; Zepbound is the same molecule approved for obesity. Both are dual GLP-1 / GIP agonists with weight-loss results that rewrote the standard of care. The pipeline pushes further: retatrutide (triple agonist, more potent early data), orforglipron (oral GLP-1, potential mass-market unlock), and Kisunla (donanemab, approved 2024 for early Alzheimer's).

Bull case	Bear case
GLP-1 / GIP leadership with Mounjaro and Zepbound	Novo Nordisk (NVO) is a credible duopoly competitor
Oral GLP-1 (orforglipron) could unlock a much larger TAM	Manufacturing capacity has been the binding constraint
Alzheimer's (Kisunla) and immunology pipeline as optionality	Payer pressure on GLP-1 pricing plus IRA negotiation overhang
Obesity TAM is enormous — roughly 1 billion candidates globally	Patient retention post-honeymoon: many discontinue within a year
Steady dividend grower with rising free cash flow	Premium valuation leaves little room for execution slips

Exact valuation is in the live widget above — a premium-priced franchise with a genuinely unprecedented launch trajectory.

Our take

Verdict: BUY — LLY is the most important pharma stock of the decade. The GLP-1 wave is real, the pipeline extends the lead, and the obesity TAM is genuinely enormous.

• GLP-1 leadership is durable. Mounjaro and Zepbound are not a single product cycle — they are the start of a category. Retatrutide pushes potency; orforglipron, if oral data holds at scale, opens the mass market beyond injectable adherence ceilings.
• Alzheimer's optionality is free. Kisunla isn't yet a blockbuster, but the neuroscience pipeline gives LLY a second leg the market is barely valuing. A dividend grower with this much pipeline optionality is rare.
• Honest caveat. Novo Nordisk is a credible competitor — share dynamics in obesity matter. Manufacturing capacity has bounded launches, and payer pressure on GLP-1 pricing is a real overhang. The valuation premium means the market is paying for execution, not promising it.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• Novo Nordisk competition: GLP-1 is effectively a duopoly. A faster Novo launch, better trial data, or a pricing war on Wegovy versus Zepbound would hit LLY's single-name valuation far harder than an index.
• Manufacturing and pricing pressure: capacity has gated launches; payer pushback and IRA negotiation on diabetes pricing remain live overhangs.
• Currency: your return is in USD but you spend rupees — see the rupee-dollar effect.

Two things people forget

• Schedule FA and Form 67 every year. Disclose LLY in Schedule FA of your ITR every year you hold it — even if bought and sold within the year, even at a loss. Non-disclosure carries Black Money Act penalties. Because LLY pays a dividend, also file Form 67 (Form 44 from TY 2026-27) every year to reclaim the 25% US withholding as an FTC. Use the Schedule FA helper.
• Position size: a single pharma name, however dominant in obesity, is not an index. Size LLY as a high-conviction satellite — the share-shift risk against Novo is real.

Bottom line

Buying LLY from India is easy and legal. What needs thought isn't the buying — it's that LLY is a Section-112 capital-gains play (12.5% after 24 months) with a small recurring dividend that drags Form 67 paperwork in every year, a US-situs asset with a $60k estate-tax trap, and a single pharma megacap that needs disciplined position sizing. The upside: the cleanest direct vehicle for the GLP-1 wave, with Alzheimer's optionality the market still seems to underweight. If your thesis is "US pharma" rather than "Lilly specifically," XLV or IHE gives broader exposure; HRTS or SLIM gives the most concentrated obesity-theme bet. For accounts and options, start at the US investing hub.

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.